Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2014 > Volume 23 Number 3 May 2014 > DEVICE EVALUATION > Early In-Vivo Hemodynamic Comparison of Supra-Annular Aortic Bioprostheses: Trifecta™ versus Perimount Magna Ease

Early In-Vivo Hemodynamic Comparison of Supra-Annular Aortic Bioprostheses: Trifecta™ versus Perimount Magna Ease

Amit Modi, Dimitrios Pousios, Syed Sadeque, Theodore Velissaris, Clifford Barlow, Steven Livesey, Geoffrey M. Tsang, Sunil K. Ohri

Wessex Cardiothoracic Centre, Southampton University Hospitals NHS Trust, Southampton, UK

Background and aim of the study: The study aim was to compare early postoperative hemodynamic gradients after supra-annular implantation of the Trifecta™ and Perimount Magna Ease aortic bioprostheses.

Methods: Between January 2010 and December 2011, a total of 235 patients (105 males, 130 females; mean age at surgery 73.8 ± 10.2 years) underwent supra-annular aortic valve replacement (AVR), with or without concomitant procedures. The patients were divided into 2 groups receiving either the Perimount Magna Ease (n = 117) or Trifecta (n = 118). Concomitant procedures were performed in 133 patients (56.6%), and 25 procedures (10.6%) were redos. Patients with postoperative severe left ventricular dysfunction and moderate to severe mitral regurgitation were excluded. Gradients were calculated pre-discharge using transthoracic echocardiography. Effective orifice area calculations were not performed. Data were collected retrospectively from hospital databases and analyzed using SPSS 17.

Results: Both groups compared well for 14 variables. Group A had a higher number of redo operations and the

patients were younger. Postoperative peak and mean gradients (in mmHg) for the Magna Ease group versus Trifecta group were: 19 mm valves, 33.5 ± 16 versus 24.7 ± 10 (p = 0.11) and 17.4 ± 6.5 versus 12.7 ± 4.4 (p = 0.05); 21 mm, 27.2 ± 9.1 versus 21.8 ± 7.2 (p = 0.001) and 13.8 ± 4.7 versus 10.7 ± 3.4 (p = 0.001); 23 mm, 25.6 ± 7.8 versus 20.1 ± 7.9 (p = 0.005) and 13 ± 4 versus 10.1 ± 4.3 (p = 0.002); 25 mm, 22.3 ± 7.8 versus 15.6 ± 5.1 (p = 0.01) and 12.8 ± 4.1 versus 8 ± 2.8 (p = 0.02). The overall mortality was 3.4%. The median hospital stay was nine days in both groups (p = 0.13). Mortality (p = 0.5), and incidences of perioperative stroke (p = 0.45), postoperative new-onset atrial fibrillation (p = 0.26) and permanent pacemaker implantation (p = 0.8) were similar in both groups.

Conclusion: Early postoperative gradients were significantly lower in patients receiving Trifecta valves, although the long-term clinical outcome and durability of the valve will require further evaluation.

The Journal of Heart Valve Disease 2014;23:325-332


Early In-Vivo Hemodynamic Comparison of Supra-Annular Aortic Bioprostheses: Trifecta™ versus Perimount Magna Ease

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.